Intensity Therapeutics Q3 net loss widens on higher R&D costs

Overview

• US biotechnology firm's Q3 net loss widened yr/yr as R&D expenses increased

• Company raised $1.5 mln in net proceeds during Q3 under its ATM facility

• Cash and cash equivalents totaled $8.5 mln at quarter-end

Outlook

• Company expects increased site activation and patient enrollment in INVINCIBLE-3 Study as funding allows

• Company targets complete enrollment in INVINCIBLE-4 Study by end of 2027

• Company expects safety data review for INVINCIBLE-4 Study in Q1 2027

Result Drivers

• TRIAL ENROLLMENT RESUMPTION - Higher R&D expenses driven by resumed patient enrollment in INVINCIBLE-3 Study

• MANUFACTURING AND COMPENSATION - R&D expenses rose due to new INT230-6 manufacturing batch, bonus accrual, and higher stock-based compensation

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Intensity Therapeutics Inc is $15.00, about 328.6% above its November 4 closing price of $3.50

Reuters Recommended Reads

• Nov 4 - Lyell Immunopharma Q3 net loss widens on higher R&D spending

• Nov 4 - Kailera Therapeutics Q3 net loss widens on higher R&D costs

• Nov 4 - Aprea Therapeutics Q3 net loss widens on higher R&D spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)